
    
      This is an open label phase II clinical study to evaluate the safety and pharmacokinetics of
      oral encochleated Amphotericin B (CAMB/MAT2203) for prevention of invasive fungal infections
      in approximately 30 patients undergoing induction therapy for AML/ALL.
    
  